Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
- Friday, June 25, 2021, 7:14
- PR Newswire
- Add a comment
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xyrem® (sodium oxybate) Xywav…
About the Author
admin has written 21717 stories on this site.